Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Zomedica Corp. is a veterinary health company focused on the development, acquisition, and commercialization of diagnostic and therapeutic products for companion animals. The company operates within the veterinary diagnostics and medical devices industry, serving primarily small and companion animal veterinary practices. Its business model emphasizes providing technology-enabled tools that support in-clinic diagnostics and non-invasive treatment options.
Zomedica’s core revenue drivers are the sales of diagnostic platforms, therapeutic medical devices, and related consumables and services. The company positions itself as a diversified veterinary technology provider rather than a single-product diagnostics firm, seeking to reduce reliance on any one platform. Zomedica was incorporated in 2013 and initially focused on developing a proprietary point-of-care diagnostic platform. Over time, the company shifted strategy toward growth through acquisitions, expanding into multiple veterinary technology and therapy categories to build a broader commercial portfolio.
Business Operations
Zomedica generates revenue through multiple operating segments centered on diagnostics and therapeutic devices. Its diagnostic offerings include the TRUFORMA® in-clinic diagnostic platform, which utilizes bulk acoustic wave technology for endocrine and other assays, and the TRUVIEW® Digital Cytology Microscope, which supports high-resolution imaging for veterinary diagnostics. These products are sold directly to veterinary clinics, with recurring revenue derived from consumables, service agreements, and software-related offerings.
On the therapeutic side, Zomedica markets PulseVet®, a regenerative shock wave therapy system used in veterinary and equine medicine, and Assisi Loop® and related products, which use pulsed electromagnetic field therapy for pain management and healing. The company primarily operates in the United States, with limited international sales through distributors. Zomedica controls its portfolio through wholly owned subsidiaries, each responsible for specific product lines and commercial operations.
Strategic Position & Investments
Zomedica’s strategy centers on expanding its commercial footprint through targeted acquisitions, internal product development, and cross-selling opportunities within its installed customer base. Major acquisitions have included Pulse Veterinary Technologies, Vetica (bringing the TRUVIEW platform), Assisi Animal Health, and Revo Squared, a veterinary telemedicine and communications platform. These acquisitions reflect a strategic emphasis on recurring revenue, diversified technology offerings, and integration of digital services into veterinary workflows.
The company continues to invest in expanding assay menus for TRUFORMA, scaling sales infrastructure, and integrating digital and therapeutic solutions across its subsidiaries. Zomedica has stated that it seeks opportunities in emerging veterinary technologies that complement its existing diagnostics and therapy portfolio. While management has articulated a long-term growth vision, the pace and financial impact of these initiatives vary, and some performance outcomes remain dependent on broader adoption trends within the veterinary market.
Geographic Footprint
Zomedica is headquartered in Ann Arbor, Michigan, and conducts the majority of its operations in North America, particularly the United States. Its primary customer base consists of U.S.-based companion animal veterinary clinics, with sales and service teams focused on domestic market penetration.
Internationally, Zomedica has a more limited presence, primarily through distribution partners and select international customers for specific products such as PulseVet. The company does not currently report significant revenue concentration outside North America, but its technologies are marketed as globally applicable, providing optionality for future geographic expansion.
Leadership & Governance
Zomedica is led by an executive team with experience in veterinary health, medical devices, and life sciences commercialization. The company’s leadership emphasizes disciplined capital allocation, operational integration of acquisitions, and building a sustainable veterinary technology platform.
Key executives include:
- Larry Heaton – Chief Executive Officer
- Robert Cohen – Interim Chief Financial Officer
- Truforma Platform leadership and subsidiary presidents – Data inconclusive based on available public sources
Zomedica’s founders are not consistently identified across public disclosures, and founding leadership details are data inconclusive based on available public sources. The board and executive team oversee corporate governance in alignment with public company reporting requirements and have articulated a strategy focused on long-term value creation through portfolio diversification and operational execution.